Get the Stockscreener App
69.28
0.72%
-0.50
After Hours:
70.70
1.42
+2.05%
Anaptysbio Inc stock is traded at $69.28, with a volume of 439.12K.
It is down -0.72% in the last 24 hours and up +20.11% over the past month.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See More
Previous Close:
$69.78
Open:
$70.93
24h Volume:
439.12K
Relative Volume:
0.73
Market Cap:
$2.02B
Revenue:
$234.60M
Net Income/Loss:
$-13.23M
P/E Ratio:
-133.08
EPS:
-0.5206
Net Cash Flow:
$19.61M
1W Performance:
+4.80%
1M Performance:
+20.11%
6M Performance:
+92.44%
1Y Performance:
+234.20%
1-Day Range:
$68.39
$72.36
1-Week Range:
$60.70
$72.36
52-Week Range:
$17.11
$73.30
Anaptysbio Inc Stock (ANAB) Company Profile
Name
Anaptysbio Inc
Sector
Industry
Phone
858-362-6295
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
69.28 | 2.03B | 234.60M | -13.23M | 19.61M | -0.5206 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Dec-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-19-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-16-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Wells Fargo | Overweight |
| Mar-12-24 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-26-24 | Initiated | BTIG Research | Buy |
| Feb-21-24 | Initiated | Stifel | Buy |
| Feb-16-24 | Initiated | Piper Sandler | Overweight |
| May-22-23 | Upgrade | JP Morgan | Underweight → Neutral |
| May-18-23 | Initiated | TD Cowen | Outperform |
| Jan-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-01-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Sep-13-22 | Downgrade | Truist | Buy → Hold |
| Sep-01-22 | Initiated | Raymond James | Outperform |
| Mar-22-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-22-21 | Initiated | H.C. Wainwright | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Mar-16-21 | Upgrade | Truist | Hold → Buy |
| Mar-09-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Feb-11-21 | Upgrade | JP Morgan | Underweight → Overweight |
| Oct-27-20 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-14-20 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-08-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-08-19 | Downgrade | SunTrust | Buy → Hold |
| Nov-08-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-21-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jun-21-19 | Downgrade | Stifel | Buy → Hold |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Apr-04-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-27-18 | Reiterated | Stifel | Buy |
| Mar-06-18 | Reiterated | Stifel | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Jan-23-18 | Reiterated | Credit Suisse | Outperform |
| Nov-15-17 | Initiated | SunTrust | Buy |
| Nov-09-17 | Initiated | Jefferies | Buy |
| Oct-11-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
View All
Anaptysbio Inc Stock (ANAB) Latest News
AnaptysBio (NASDAQ:ANAB) Reaches New 52-Week HighHere's Why - MarketBeat
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? - Yahoo Finance
Piper Sandler Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $93 - Moomoo
GSK subsidiary Tesaro, AnaptysBio provide update on contract claim litigation - MSN
ANAB Maintained by Piper Sandler -- Price Target Lowered to $93 - GuruFocus
AnaptysBio CEO to appear at royalty company virtual conference - Stock Titan
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference - GlobeNewswire
Biotech Momentum Builds Around AnaptysBio Shift - Kalkine Media
Piper Sandler Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat
AnaptysBio (ANAB) Is Up 13.4% After Court Upholds Jemperli Royalty Rights In Tesaro Dispute - Yahoo Finance
AnaptysBio stock rallies as Delaware court tosses Tesaro breach claim - MSN
AnaptysBio, Inc. (ANAB) may report negative earnings: Know the trend ahead of Q1 release - MSN
AnaptysBio (NASDAQ:ANAB) Passes Minervini Trend Template and High Growth Momentum Screen - ChartMill
AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Down 14.7% in April - MarketBeat
ANAB Stock Price, Quote & Chart | ANAPTYSBIO INC (NASDAQ:ANAB) - ChartMill
AnaptysBio rises after completing First Tracks spinoff - MSN
Director Susannah Gray receives 11,250 RSUs at AnaptysBio (ANAB) - Stock Titan
Barclays Initiates Coverage of AnaptysBio (ANAB) with Overweight Recommendation - MSN
ANAB SEC FilingsAnaptysbio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
AnaptysBio (ANAB) surges 14.8%: Is this an indication of further gains? - MSN
Rare skin disease drug study appears in NEJM Evidence before FDA date - Stock Titan
AnaptysBio (NASDAQ: ANAB) details spin-off, pay and board changes - Stock Titan
Fenwick Secures Chancery Court Victory for AnaptysBio in Licensing Dispute - fenwick.com
ANAB Rated Outperform by Leerink Partners -- Price Target Raised to $85 - GuruFocus
AnaptysBio (NASDAQ:ANAB) Hits New 1-Year HighTime to Buy? - MarketBeat
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence - Sahm
Why Is AnaptysBio Stock Soaring Monday?AnaptysBio (NASDAQ:ANAB) - Benzinga
AnaptysBio (NASDAQ:ANAB) Trading 11.2% HigherTime to Buy? - MarketBeat
GSK subsidiary Tesaro, AnaptysBio provide update on contract claim litigation (GSK:NYSE) - Seeking Alpha
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains? - Yahoo Finance
GSK (NYSE: GSK) outlines TESARO–AnaptysBio dostarlimab litigation status and Jemperli growth - Stock Titan
AnaptysBio (ANAB) Expected to Announce Earnings on Monday - MarketBeat
GSK Subsidiary Wins Motion Against AnaptysBio in Contract Dispute - GuruFocus
GSK Subsidiary TESARO Faces Setback in AnaptysBio Litigation, Jemperli Growth Remains Strong - AskTraders
Court favors AnaptysBio dismissing anticipatory breach claim - The Pharma Letter
GSK subsidiary wins dismissal of AnaptysBio anticipatory breach claim (GSK:NYSE) - Seeking Alpha
TESARO, a GSK subsidiary, provides update on AnaptysBio, Inc. litigation - GSK
GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio - Proactive financial news
US court rules against GSK in dispute with AnaptysBio - Sharecast.com
GSK says unit Tesaro's claim for declaratory judgment against AnaptysBio unchanged - marketscreener.com
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
AnaptysBio Completes Spin-Off of First Tracks Biotherapeutics: Key Financial Impacts and Pro Forma Results - Minichart
Delaware court dismisses Tesaro breach claim against AnaptysBio By Investing.com - Investing.com Australia
AnaptysBio (NASDAQ:ANAB) Stock Rating Upgraded by Wall Street Zen - MarketBeat
GSK Faces Legal Setback as AnaptysBio Wins Court Ruling - GuruFocus
Anaptysbio Inc Stock (ANAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):